Metadata record for the manuscript: Olaparib for Metastatic Breast Cancer in a Patient with a Germline PALB2 Variant

<b>Summary</b>This metadata record provides details of the data supporting the claims of the related manuscript. The related study reports a patient with germline/somatic BRCA1/2 wild-type metastatic breast cancer (MBC), who had a dramatic response to the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib of at least eight months’ duration. The patient was a 37-year-old woman with recurrent, hormone receptor-positive, HER2-negative MBC that had progressed despite hormonal therapy and palbociclib.<br><br><b>Data description and access</b>The tumour DNA sequencing data has been deposited in <i>NCBI Sequence Read Archive</i> and is available via accession: https://identifiers.org/ncbi/bioproject:PRJNA635377. The tumour DNA next generation sequencing (NGS) analysis is contained in the spreadsheet <b>Tumor DNA analysis.xlsx</b>, which is included with this data record; this file summarises the mutant allele frequency and copy number variations that were detected by NGS. The germline DNA sequencing can not be shared due to German data protection law considerations designed to safeguard patient anonymity. However, the authors confirm there were no other rare germline variants detected besides the reported PALB2 variant, which has previously been described and is available in <i>dbSNP </i>under this accession: https://identifiers.org/dbsnp:rs587782462.The data underlying Figure 1 in the related manuscript is contained in the spreadsheet <b>CA 15-3.xlsx</b>, included with this data record. <br><br><b>Ethics statement</b>Off-label treatment with olaparib in this patient with MBC lacking germline BRCA1/2 sequence variants affecting function was provided as compassionate use in the palliative setting in line with national regulations and did not require ethics committee approval. The patient provided written informed consent prior to initiation of treatment.